Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Saline, 1.0 ml Clear all
Not listed Phase 1 Interventional

Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects

NCT01428596
View directory record Official record
Conditions
HIV Infections
Interventions
HIVAX, saline solution
Biological
Lead sponsor
GeneCure Biotechnologies
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults

NCT04776317
View directory record Official record
Conditions
COVID-19
Interventions
ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Safety of RNS60 in Large Vessel Occlusion Stroke Patients Undergoing Endovascular Thrombectomy

NCT04693715
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Chicago, Illinois • Portland, Oregon • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

NCT00111605
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA, HIV-1 gag DNA plus IL-12 DNA adjuvant, CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine), Sodium chloride injection (0.9%)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2008
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 24, 2026, 5:42 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation

NCT02802436
View directory record Official record
Conditions
Healing of Extraction Socket
Interventions
Extraction with socket graft
Procedure
Lead sponsor
Boston University
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 24, 2026, 5:42 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

NCT06022224
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 24, 2026, 5:42 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

NANOVAE to Treat Knee Osteoarthritis (KOA)

NCT06606561
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF), 0.9% Sodium Chloride Injection, USP
Drug
Lead sponsor
Nova Vita Laboratory
Industry
Eligibility
21 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 24, 2026, 5:42 AM EDT
Terminated Not applicable Interventional

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

NCT01996111
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
Procedure
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

NCT00319592
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
ChimeriVax™-JE vaccine, JE-VAX® vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 48 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2012 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

NCT05196919
View directory record Official record
Conditions
Facet Joint Pain, Back Pain, Inflammation
Interventions
XT-150, Placebo
Biological
Lead sponsor
Xalud Therapeutics, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
3
States / cities
Napa, California • Santa Monica, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 24, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Results available

TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)

NCT03477903
View directory record Official record
Conditions
Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance
Interventions
TAK-954, Metoclopramide, Normal Saline
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
14
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Peoria, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

NCT00223899
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
VCL-IM01 (encoding IL-2) with Electroporation
Genetic
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Mobile, Alabama • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 24, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

NCT00866476
View directory record Official record
Conditions
Shigella
Interventions
CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
rLP2086, Havrix (HAV), Saline
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 18 Years
Enrollment
3,596 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Harrisburg, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Sep 24, 2026, 5:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Denosumab for Type 1 Diabetes

NCT06524960
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Duarte, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy

NCT01843504
View directory record Official record
Conditions
Chronic Patellar Tendinopathy, Chronic PT
Interventions
platelet rich plasma, saline
Biological · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Results available

Determining the Prognostic Value of Continuous Intrathecal Infusion

NCT03523000
View directory record Official record
Conditions
Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
Interventions
Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS)
Other · Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Sep 24, 2026, 5:42 AM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

NCT01482221
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD6765 iv, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Chino, California • Lond Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 24, 2026, 5:42 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Use of Tranexamic Acid in Facial Fillers

NCT04373603
View directory record Official record
Conditions
Injection Site Bruising
Interventions
Tranexamic acid, Saline, Hyaluronic acid
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 24, 2026, 5:42 AM EDT
Withdrawn Phase 3 Interventional

Pulmozyme in Cystic Fibrosis With Sinusitis

NCT01155752
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme single use ampule, placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 24, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

NCT02117934
View directory record Official record
Conditions
Healthy
Interventions
HEPLISAV, Engerix-B
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
8,374 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 24, 2026, 5:42 AM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Feasibility of Polychromatic Light Emitting Diode System to Reduce Pain

NCT03246282
View directory record Official record
Conditions
Pain
Interventions
UVL1000 Treatment Station, Normal Saline 0.9% Infusion Solution Bag, Peripheral Catheterization
Device · Drug
Lead sponsor
John W. Reeves, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 24, 2026, 5:42 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 24, 2026, 5:42 AM EDT